Phospho-PGR (Ser294) Antibody

What is the biological significance of PR Ser294 phosphorylation?

Progesterone receptor Ser294 serves as a critical hormone-dependent phospho-acceptor site that functions as an extracellular signaling "sensor." This phosphorylation event has multiple downstream consequences that significantly alter PR function:

• Promotes nuclear retention of the receptor

• Enhances transcriptional activity on select promoters

• Triggers ubiquitin-dependent proteasomal degradation

• Antagonizes Lys388 SUMOylation (a repressive modification)

• Creates hyperactive receptors on select promoters in response to ligand

Research demonstrates that p44/p42 MAP kinases primarily mediate phosphorylation of PR at Ser294 following hormone binding . This phosphorylation event couples heightened transcriptional activity to rapid proteasome-dependent turnover, reflecting a sophisticated regulatory mechanism .

How do PR-A and PR-B isoforms differ in their Ser294 phosphorylation patterns?

PR isoform-specific phosphorylation at Ser294 represents a significant regulatory distinction:

Interestingly, while PR-A is not typically phosphorylated at Ser294 in intact cells, this site in PR-A can be phosphorylated in vitro using recombinant PR-A proteins . This highlights the importance of protein-protein interactions and associated signaling complexes containing protein kinases as major determinants of PR isoform specificity. Recent research has revealed that in some contexts, particularly related to cancer stem cells, PR-A can show robust Ser294 phosphorylation relative to PR-B, with significant functional consequences .

What are the optimal experimental conditions for detecting phospho-Ser294 PR using Western blotting?

For optimal detection of phospho-Ser294 PR via Western blotting:

• Sample Preparation:

  • Harvest cells at appropriate timepoints after hormone treatment (consider both early timepoints to observe initial phosphorylation and later timepoints to monitor degradation)

  • Use phosphatase inhibitors in lysis buffer to preserve phosphorylation status

  • Consider using proteasome inhibitors (lactacystin, calpain inhibitor I) if studying degradation dynamics

• Western Blotting Parameters:

  • Recommended dilution: 1:500-1:2000 (varies by antibody manufacturer)

  • Expected molecular weights: ~90 kDa (PR-A), ~118 kDa (PR-B)

  • Include appropriate controls (unphosphorylated PR, phosphorylation-deficient mutants like S294A)

• Verification Strategies:

  • Use MEK inhibitors (U0126) to eliminate Ser294 phosphorylation as a specificity control

  • Consider lambda phosphatase treatment of duplicate samples to confirm phospho-specificity

  • When studying hormone-dependent phosphorylation, include both vehicle control and R5020 (progesterone agonist) treated samples

Note that phosphorylated PR will often appear as an upshift on SDS-PAGE gels due to reduced electrophoretic mobility, which reflects increased phosphorylation at multiple serine residues .

How can I validate the specificity of phospho-Ser294 PR antibody detection in my experimental system?

Validating antibody specificity is critical for confident interpretation of phospho-PR data:

• Genetic Approaches:

  • Compare staining/signal between wild-type PR and PR-S294A mutant cells

  • Use siRNA/shRNA knockdown of PR followed by re-expression of either wild-type or S294A mutant

  • For advanced validation, implement CRISPR-Cas9 to create endogenous S294A mutations

• Pharmacological Approaches:

  • Treat cells with specific MEK inhibitors (U0126, SB190) to block Ser294 phosphorylation

  • Compare results from multiple phospho-specific antibodies from different vendors

  • Use lambda phosphatase treatment to remove all phosphate groups as a negative control

• Cell-Based Validation:

  • Monitor phosphorylation patterns following EGF treatment (known to induce robust PR Ser294 phosphorylation)

  • Compare phosphorylation patterns in cell lines with different levels of MAPK/CDK2 activity

  • Use Cell-Based ELISA approaches for quantitative assessment of specificity

The combination of these approaches provides strong validation of antibody specificity, essential for confident interpretation of experimental results.

How does Ser294 phosphorylation influence PR target gene selection and transcriptional output?

Phosphorylation of PR at Ser294 fundamentally alters its transcriptional program through multiple mechanisms:

• Altered Promoter Selection:

  • Phospho-Ser294 PR exhibits distinct binding patterns in ChIP assays compared to non-phosphorylated PR

  • SUMO-deficient PR (mimicking phospho-Ser294 PR) binds to unique gene promoters/enhancers

  • Genes specifically upregulated by phospho-PR include MSX2, RGS2, MAP1A, and PDK4, which are amplified in breast carcinomas

• Transcriptional Hyperactivity:

  • Phospho-Ser294 receptors are transcriptionally hypersensitive to low concentrations of ligand on select promoters

  • This hypersensitivity maps to phospho-Ser294 antagonism of Lys388 sumoylation

  • Phosphorylated/desumoylated receptors are active on a subset of ligand-independent PR-target gene promoters

• Altered Cofactor Recruitment:

  • FOXO1, a PR target gene and coactivator, promotes PR phosphorylation and influences transcriptional outcomes

  • Inhibition of FOXO1 (using AS1842856) blunts phosphorylated PR and alters transcriptional patterns

Research demonstrates that mutation of PR Ser294 to alanine (S294A) renders PR virtually transcriptionally inactive when measured on endogenous genes, underscoring the critical role of this phosphorylation site in PR function .

What is the relationship between PR Ser294 phosphorylation and cancer stem cell (CSC) biology in breast cancer?

Emerging research reveals a complex relationship between phospho-Ser294 PR and cancer stem cell phenotypes:

• Isoform-Specific Effects:

  • PR-A appears to be a dominant driver of CSC expansion in breast cancer cells

  • PR-A phosphorylation at Ser294 is required for CSC behavior as measured in secondary tumorsphere assays

  • PR-B is a more potent driver of breast cancer cell proliferation

• Functional Consequences:

  • PR-A+ tumorspheres enriched for phospho-Ser294 show increased aldehyde dehydrogenase (ALDH) activity

  • These cells demonstrate enrichment for CD44+/CD24− and CD49f+/CD24− cell populations (CSC markers)

  • Mutation of PR-A Ser294 to Ala (S294A) blocks CSC expansion but paradoxically promotes cell proliferation

• Molecular Mechanisms:

  • Progestin promotes heightened expression of known CSC-associated target genes in PR-A+ but not PR-B+ cells cultured as tumorspheres

  • FOXO1 appears to cooperate with both PR isoforms to inhibit proliferation while promoting CSC behavior

  • This suggests unique functions of PR isoforms as modulators of distinct and opposing pathways

These findings suggest that PR phosphorylation status may be a critical determinant in the balance between proliferation and stemness in breast cancer, with significant implications for tumor progression and therapy resistance.

How can I design experiments to study the functional consequences of PR Ser294 phosphorylation in breast cancer models?

A comprehensive experimental approach should include:

• Cellular Models:

  • Compare T47D and MCF-7 cells expressing either wild-type PR or phosphorylation-deficient mutants (S294A)

  • Include double mutants (KRSA, containing mutations at both Ser294 and Lys388) to dissect SUMO-dependent effects

  • Consider BT-474 cells (ERBB2/HER2-positive) which show strong phospho-PR signaling patterns

• Functional Assays:

  • Tumorsphere formation assays to assess cancer stem cell properties

  • Proliferation assays (MTT, BrdU incorporation) to measure cell growth

  • Migration and invasion assays to assess metastatic potential

  • Gene expression profiling to identify phospho-PR-dependent transcriptional programs

• Intervention Approaches:

  • Pharmacological: MAPK inhibitors (U0126, SB190), FOXO1 inhibitor (AS1842856), PR antagonist (onapristone)

  • Genetic: CRISPR-mediated mutation of Ser294, siRNA against pathway components

  • Combinatorial: Assess synergistic effects of targeting both PR and MAPK/ERBB2 pathways

• In Vivo Validation:

  • Xenograft models comparing tumors expressing wild-type versus S294A PR

  • Patient-derived xenografts with characterized PR phosphorylation status

  • Correlation with human tumor datasets to identify PR phosphorylation signatures

This multi-faceted approach allows for comprehensive characterization of phospho-PR biology and its relevance to breast cancer progression.

What are the potential mechanisms underlying the differential phosphorylation of PR-A versus PR-B at Ser294?

Several mechanisms may explain the isoform-specific phosphorylation patterns:

• Structural Differences:

  • PR-A lacks the first 164 amino acids present in PR-B (N-terminal domain)

  • This structural difference may alter protein conformation and accessibility of Ser294 to kinases

  • Differential protein folding may expose or mask phosphorylation sites in a context-dependent manner

• Differential Protein Interactions:

  • Isoform-specific cofactor recruitment may influence kinase proximity and activity

  • PR-A and PR-B have distinct interactomes that may include different levels of kinases or phosphatases

  • The presence of specific scaffolding proteins may facilitate or inhibit phosphorylation events

• Subcellular Localization:

  • PR isoforms may localize differently within cellular compartments

  • This could affect their proximity to active kinases or phosphatases

  • Differential nuclear-cytoplasmic shuttling may expose PR to different enzymatic environments

• Context-Dependent Regulation:

  • Tumor microenvironment may alter signaling pathways differently for each isoform

  • In cancer stem cell-like contexts, PR-A appears to become more heavily phosphorylated at Ser294

  • Growth factor signaling (particularly ERBB2/HER2) may selectively enhance PR-A phosphorylation in certain contexts

Understanding these mechanisms could provide insights into new therapeutic approaches targeting specific PR isoforms in different cellular contexts.

How do I interpret apparent contradictions in phospho-Ser294 PR data between different experimental systems?

When facing contradictory results across experimental systems, consider these methodological factors:

• Cell Line Variations:

  • Different breast cancer cell lines have distinct signaling backgrounds (MAPK/Akt/mTOR activity levels)

  • Expression ratios of PR-A:PR-B vary widely across cell models and can affect experimental outcomes

  • Genetic backgrounds (p53 status, PTEN status, etc.) can significantly impact PR signaling

• Experimental Conditions:

  • Timing of observations is critical—phosphorylation precedes degradation, potentially giving opposing results

  • Ligand concentrations vary across studies (physiological vs. pharmacological)

  • Growth conditions (2D vs. 3D culture, serum levels) alter baseline kinase activity

• Technical Considerations:

  • Antibody specificity varies between manufacturers and lots

  • Detection methods have different sensitivities (Western blot vs. mass spectrometry vs. ELISA)

  • Sample preparation methods may preserve or disrupt phosphorylation status

• Data Analysis Approaches:

  • Normalization methods affect quantification of phosphorylation signals

  • Some studies examine phospho:total PR ratios while others report absolute phospho-PR levels

  • Statistical approaches vary in their ability to detect significant differences

When specific contradictions arise, systematically examine these factors and consider replicating key experiments under standardized conditions to resolve discrepancies.

How might phospho-Ser294 PR status be utilized as a biomarker in breast cancer patient stratification?

Phospho-Ser294 PR status offers potential as a clinical biomarker:

• Prognostic Value:

  • Abundant phosphorylated Ser294 PR levels have been observed in a majority (54%) of luminal breast tumor samples

  • Phospho-PR-driven gene signatures are associated with ERBB2-positive tumors and decreased patient survival

  • The balance between PR-A and PR-B phosphorylation status may predict late recurrence risk

• Predictive Applications:

  • May predict response to PR antagonists or selective PR modulators

  • Could identify patients who would benefit from combined PR and MAPK pathway inhibition

  • Might help identify patients at risk for developing endocrine resistance

• Implementation Considerations:

  • Immunohistochemistry using phospho-specific antibodies on tumor sections

  • Quantitative assessment using phospho-PR Cell-Based ELISA on fresh tumor samples

  • Gene expression signatures as surrogates for phospho-PR activity

• Challenges to Address:

  • Standardization of phospho-PR detection methods across clinical laboratories

  • Establishment of clinically relevant cutoffs for positivity

  • Integration with existing biomarkers (ER, PR, HER2, Ki-67)

Research indicates that a gene signature specifically upregulated by SUMO-deficient PR (mimicking phospho-PR) is significantly associated with genes highly expressed in ERBB2-positive human breast tumors, providing a strong rationale for further development of phospho-PR as a clinically relevant biomarker .

What are the methodological considerations for studying phospho-Ser294 PR in patient-derived specimens?

Working with patient samples requires special considerations:

• Specimen Collection and Processing:

  • Immediate fixation is critical as phosphorylation status can change rapidly post-excision

  • Consider using phosphatase inhibitors during sample collection

  • Flash-freezing portions of specimens can preserve phosphorylation status better than FFPE processing

• Detection Methods:

  • Immunohistochemistry: Requires extensive validation and optimization of antigen retrieval methods

  • Proximity ligation assay: Can provide sensitive detection of phospho-PR with cellular resolution

  • Reverse-phase protein arrays: Allow quantitative assessment across multiple samples

• Validation Approaches:

  • Include positive controls (cell lines with known phospho-PR status)

  • Use paired antibodies (total PR and phospho-PR) on serial sections

  • Consider parallel analysis by Western blotting when possible

• Data Interpretation:

  • Account for tumor heterogeneity by analyzing multiple regions

  • Consider the PR-A:PR-B ratio in the interpretation of phospho-PR signals

  • Correlate with activation status of upstream kinases (phospho-MAPK, phospho-CDK2)

These methodological considerations are essential for generating reliable and clinically meaningful data from patient specimens.

What emerging technologies might enhance our ability to study PR Ser294 phosphorylation dynamics?

Several cutting-edge approaches show promise for advancing phospho-PR research:

• Advanced Imaging Technologies:

  • Live-cell imaging with phospho-specific fluorescent biosensors

  • Super-resolution microscopy to visualize PR phosphorylation in nuclear subdomains

  • FRET-based approaches to monitor real-time phosphorylation events

• Single-Cell Technologies:

  • Single-cell phosphoproteomics to capture cellular heterogeneity

  • Spatial transcriptomics to correlate phospho-PR localization with gene expression patterns

  • Single-cell ChIP-seq to map phospho-PR genomic binding at single-cell resolution

• Computational Approaches:

  • Machine learning algorithms to predict phosphorylation dynamics

  • Network modeling to integrate phospho-PR signaling with other pathways

  • Patient-specific digital twins to model individual tumor phospho-signaling networks

• Therapeutic Development Platforms:

  • PROTAC technology to selectively degrade phosphorylated PR isoforms

  • Structure-based drug design targeting phospho-PR conformations

  • Combinatorial drug screening platforms to identify synergistic targets with phospho-PR inhibition

These emerging technologies promise to deepen our understanding of PR phosphorylation dynamics and potentially reveal new therapeutic opportunities.